Results 1 to 10 of about 3,966 (138)

Comparative efficacy of mepolizumab and benralizumab in severe eosinophilic asthma: a retrospective cohort study [PDF]

BMC Pulmonary Medicine
Purpose This real-world study compared the efficacy and the proportion of patients attaining the criteria constituting clinical remission at 12 months between mepolizumab and benralizumab in patients with severe eosinophilic asthma.
Wei-Chun Huang, Yi-Luen Shen, Wen-Chien Cheng, Chien-Wen Huang, Chia-Hung Chen, Chih- Yen Tu, Wu-Huei Hsu   +6 more
doaj   +2 more sources

Eosinophilic Depletion with Benralizumab, Mepolizumab, and Depemokimab: A Modeling Study [PDF]

Journal of Asthma and Allergy
Pradeep B Lukka,1 Robert C Penland,1 Ari Brekkan,2 Rami Ayoun Alsoud,2 Sherri So,3 David W Boulton1 1Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, USA ...
Lukka PB, Penland RC, Brekkan A, Ayoun Alsoud R, So S, Boulton DW   +5 more
doaj   +2 more sources

Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis

Frontiers in Pharmacology, 2022
Two types of interleukin (IL)-5 antibody biologics, anti-IL-5 antibodies (mepolizumab) and anti-IL-5α receptor antibodies (benralizumab), are indicated for severe asthma.
Yasuhiko Koga, Haruka Aoki-Saito, Yosuke Kamide, Makiko Sato, Hiroaki Tsurumaki, Masakiyo Yatomi, Tamotsu Ishizuka, Takeshi Hisada   +7 more
doaj   +1 more source

Pharmacoeconomic analysis of using benralizumab for treatment of severe asthma in inpatient and outpatient settings

Фармакоэкономика, 2022
Objective: evaluation of the pharmacoeconomic feasibility of using benralizumab in the form of autoinjector (pen-injector device) in outpatient facilities compared with its use in the form of a syringe in hospital settings for the treatment of severe ...
M. V. Zhuravleva, S. N. Avdeev, Yu. V. Gagarina, T. V. Marin   +3 more
doaj   +1 more source

Pretreatment Frequency of Circulating Th17 Cells and FeNO Levels Predicted the Real-World Response after 1 Year of Benralizumab Treatment in Patients with Severe Asthma

Biomolecules, 2023
Benralizumab treatment reduces exacerbations and improves symptom control and quality of life in patients with severe eosinophilic asthma. However, the determination of biomarkers that predict therapeutic effectiveness is required for precision medicine.
Yuuki Sandhu, Norihiro Harada, Hitoshi Sasano, Sonoko Harada, Shoko Ueda, Tomohito Takeshige, Yuki Tanabe, Ayako Ishimori, Kei Matsuno, Sumiko Abe, Tetsutaro Nagaoka, Jun Ito, Asako Chiba, Hisaya Akiba, Ryo Atsuta, Kenji Izuhara, Sachiko Miyake, Kazuhisa Takahashi   +17 more
doaj   +1 more source

Safety and efficacy of monoclonal antibodies targeting IL-5 in severe eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials

Health Sciences Review, 2023
Background: Recently, mepolizumab and benralizumab have been approved for the treatment of severe eosinophilic asthma. Objective: Thus, the main objective of the current study was to find out the exact efficacy and safety profile of mepolizumab and ...
Noor Alam, S. Latha, Anoop Kumar
doaj   +1 more source

Effects of anti‐IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real‐life multicentre study (BIONIGE)

Clinical and Translational Allergy, 2022
Background Mepolizumab and benralizumab are clinically effective biological treatments for severe eosinophilic asthmatic patients by hampering eosinophilic inflammation. The effects of these compound on the immunoglobulin (Ig)E T2 component are virtually
Marco Contoli, Pierachille Santus, Francesco Menzella, Cindy Rocchi, Dejan Radovanovic, Federico Baraldi, Chiara Martelli, Serena Casanova, Carlo Barbetta, Claudio Micheletto, Nicola Scichilone, Bianca Beghè, Elisiana Carpagnano, Alberto Papi   +13 more
doaj   +1 more source

Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis

Respiratory Medicine Case Reports, 2022
Eosinophils play an important pathogenetic role in the development of eosinophilic granulomatosis with polyangiitis (EGPA). EGPA has long been treated with systemic corticosteroids and immunosuppressive agents.
Osamu Matsuno, Seijiro Minamoto
doaj   +1 more source

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts

Allergy, Asthma & Clinical Immunology, 2021
Background Mepolizumab and benralizumab are biologics approved for severe eosinophilic asthma. Mepolizumab is an anti-interlukin-5 (IL-5) antibody while benralizumab is an anti-interleukin-5 receptor alpha (IL-5Rα) antibody targeting the IL-5 receptor on
Arian Ghassemian, Jane Jiyoon Park, Michael W. Tsoulis, Harold Kim   +3 more
doaj   +1 more source

Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study

BMC Pulmonary Medicine, 2020
Background Benralizumab, an anti-interleukin-5 (IL-5) receptor α monoclonal antibody, significantly reduces the number of annual exacerbations and oral corticosteroid (OCS) maintenance doses for patients with severe eosinophilic asthma (SEA).
Takanori Numata, Hanae Miyagawa, Saiko Nishioka, Keitaro Okuda, Hirofumi Utsumi, Mitsuo Hashimoto, Shunsuke Minagawa, Takeo Ishikawa, Hiromichi Hara, Jun Araya, Kazuyoshi Kuwano   +10 more
doaj   +1 more source